

Peptide agonist of adiponectin receptors useful in treating T2D and obesity-linked pathologies

■ PATENT

Pending EP patent application

Priority date: 2018-12-23

■ LICENSING

Exclusive, non-exclusive licences and research collaborations

■ INVENTORS

BURTEA Carmen

LAURENT Sophie

CROMBEZ Deborah

Laboratory of General, Organic and Biomedical Chemistry

■ PROBLEM

Obesity can lead to serious complications (i.e., diabetes, CVD) in the absence of an adequate treatment, which remains to be developed.

Adiponectin, an adipokine secreted by the adipose tissue, **decreases in diabetic and obese patients**. Its replenishment has an anti-diabetic effect. This adipokine has also been reported to induce beneficial effects in pathologies, such as obesity, MS, CVD, fatty liver disease and liver fibrosis.

■ SOLUTION

A peptide agonist of AdipoR1 and 2 that modulate adiponectin signaling pathways and could regulate glucose and lipid metabolism of obese and diabetic patients.

■ MARKETS

T2D and obesity associated pathologies treatment

Contact

Marlène GENLAIN
AVRE
+32 65 37 47 78
marlene.genlain@umons.ac.be